L. Brugieres, P. Quartier, M. C. Le Deley, H. Pacquement, Y. Perel, C. Bergeron, et al., “Relapses of Childhood Anaplastic Large-Cell Lymphoma: Treatment Results in a Series of 41 Children—A Report from the French Society of Pediatric Oncology,” Annals of Oncology, Vol. 11, No. 1, 2000, pp. 53-58. doi:10.1023/A:1008352726155

has been cited by the following article:

• TITLE: Long Lasting Efficiency of Monthly Vinblastine in a Case of Relapsed Anaplastic Large Cell Lymphoma

  AUTHORS: Ratha Mlis, Matthias Schell, Perrine Marec Bérard, Nathalie Bleyzac, Didier Frappaz

  KEYWORDS: Anaplastic Large Cell Lymphoma; Vinblastine

  JOURNAL NAME: Open Journal of Blood Diseases, Vol.3 No.2, June 25, 2013

  ABSTRACT: Nearly 40% of children with Anaplastic Large cell lymphomas will relapse after a first-line strategy with short-pulse chemotherapy and reach a second remission in 30% to 60% with second line therapies including maintenance treatment with vinblastine or allogeneic hematopoietic stem-cell transplantation. The authors report a heavily pretreated case in second relapse who was maintained in third remission for 8 years with monthly vinblastine. He relapsed 16 weeks after discontinuation. This case demonstrates that monthly treatment with vinblastine may be sufficient to maintain a minimal disease. Oral compounds are now available and should be discussed in such situations.